США - англійська - NLM (National Library of Medicine)

fresenius kabi usa, llc - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 100 ug in 5 ml - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have

США - англійська - NLM (National Library of Medicine)

par pharmaceutical inc. - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 200 ug in 5 ml - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have

США - англійська - NLM (National Library of Medicine)

par pharmaceutical companies, inc. - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 200 ug in 5 ml - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established. caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating. studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities. therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of non-treatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have n

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

nova laboratories ltd - mercaptopurine - oral suspension - 20mg/1ml

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - mercaptopurine monohydrate 10mg - tablet - 10 mg - active: mercaptopurine monohydrate 10mg excipient: lactose monohydrate magnesium stearate starch

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - mercaptopurine - oral tablet - 50mg

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

fontus health ltd - mercaptopurine - oral tablet - 50mg

Мальта - англійська - Medicines Authority

medicem limited 57a ta’ maggi industrial estate, st. leonard street, xghajra l/o zabbar, zbr 2305, malta - mercaptopurine - tablet - mercaptopurine 50 mg - antineoplastic agents

Мальта - англійська - Medicines Authority

aspen pharma trading limited 3016 lake drive city west businees campus dublin 24, ireland - mercaptopurine - tablet - mercaptopurine 50 mg - antineoplastic agents

Мальта - англійська - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mercaptopurine - tablet - mercaptopurine 50 mg - antineoplastic agents